Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-Genentech-03-02-2016-21:46:44:019-117 - samples

ABSTRACT: PacBio data for mesothelioma cell line NCI-H2595.

PROVIDER: EGAD00001001917 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Immunopeptidomics of malignant mesothelioma to identify target antigens for T cell Immunotherapy

Project description:Immunoaffinity purification was performed on human mesothelioma cell lines NCI-H2452, NCI-H28, MSTO-211H and JL1, on murine mesothelioma cell line AB12, as well as on mesothelioma samples from two patients (including tumor and benign tissues). Thereafter Immunopeptidomics by Mass Spectrometry on a Tims TOF Pro revealed the MHC peptide landscape of mesothelioma.

2023-09-08 | PXD038273 | Pride

ena-DATASET-Genentech-03-02-2016-21:43:58:725-115 - samples

Project description:RNA-Seq data for Mesothelioma.

| EGAD00001001915 | EGA

ena-DATASET-Genentech-03-02-2016-21:42:37:200-113 - samples

Project description:Exome sequencing data for Mesothelioma

| EGAD00001001913 | EGA

ena-DATASET-Genentech-03-02-2016-21:45:26:816-116 - samples

Project description:Targeted sequencing using SPET for Mesothelioma.

| EGAD00001001916 | EGA

ena-DATASET-Genentech-03-02-2016-21:43:26:802-114 - samples

Project description:RNA-seq data for mesothelioma cell lines after spliceostatin (SSA) or control (DMSO) treatment.

| EGAD00001001914 | EGA

Next Generation Sequencing Quantitative Analysis of TEAD Inhibitors in NCI-H226 cells

Project description:Purpose: The goal of this study is to understand the signaling pathway alteration in NCI-H226 cells treated with TEAD inhibitors. Methods: Mesothelioma cell line NCI-H226 was chosen to be treated with TEAD inhibitors at 1μM for 24 hours. Total RNA was isolated for the analysis. RNA samples were sent to Novogen for library construction, RNA sequencing and raw data process. Conclusions: Our study privides gene expression profiling evidence to validate TEAD inhibitors to block TEAD transcriptional activity in mesothelioma cells.

2022-10-15 | GSE215114 | GEO

Next Generation Sequencing Quantitative Analysis of TEAD Palmitoylation Inhibitor TM2 in NCI-H226 cells

Project description:Purpose: The goal of this study is to understand the signaling pathway alteration in NCI-H226 cells treated with new TEAD autopalmitoylation inhibitor TM2, and to further validate TEAD inhibitor for specifity in TEAD-YAP interuption. Methods: Mesothelioma cell line NCI-H226 was chosen to be treated with TEAD palmitoylation inhibitor TM2 at 1μM for 24 hours. Total RNA was isolated for the analysis. RNA samples were sent to Novogen for library construction, RNA sequencing and raw data process. Conclusions: Our study privides gene expression profiling evidence to validate our TEAD palmitoylation inhibitor TM2 as specific small molecule to block TEAD transcriptional activity in mesothelioma cells.

2024-05-01 | GSE203421 | GEO